HLN (Haleon) ROE % Adjusted to Book Value: 5.16% (As of Dec. 2025)


HLN Haleon PLC HLN
70 GF Score
Price $9.82
GF Value $9.74
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Haleon ROE % Adjusted to Book Value?

Haleon HLN +4.47% 70 ROE % Adjusted to Book Value is 5.16% as of Dec. 2025. GuruFocus rates HLN with a GF Score™ of 70/100 and a GF Value™ of $9.74 (Fairly Valued). The stock has 3 warning signs investors should review.

Haleon's ROE % for the quarter that ended in Dec. 2025 was 10.57%. Haleon's PB Ratio for the quarter that ended in Dec. 2025 was 2.05. Haleon's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was 5.16%.

Haleon ROE % Adjusted to Book Value Related Terms

Haleon ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Haleon's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haleon ROE % Adjusted to Book Value Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 2.53 3.59 4.17 5.13

Haleon Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.43 4.93 4.13 4.84 5.16

HLN vs ZTS, UTHR, VTRS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haleon ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haleon's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Haleon's ROE % Adjusted to Book Value falls into.


HLN
70GF Score
Haleon PLC HLN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haleon ROE % Adjusted to Book Value Calculation

Haleon's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=10.52% / 2.05
=5.13%

Haleon's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=10.57% / 2.05
=5.16%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 5.16% mean?
Haleon (HLN) has a ROE % Adjusted to Book Value of 5.16% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Haleon and its competitors.
Is Haleon's ROE % Adjusted to Book Value too high?
Haleon's current ROE % Adjusted to Book Value is 5.16%. Overall, Haleon has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haleon's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Haleon's ROE % Adjusted to Book Value of 5.16% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Haleon and its competitors. Haleon's current ROE % Adjusted to Book Value is 5.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Based on GuruFocus' analysis, Haleon (HLN) is currently considered Fairly Valued. The stock's GF Value™ is $9.74, compared to a current price of $9.82 — trading 0.8% above its estimated fair value. The current ROE % Adjusted to Book Value is 5.16%. Haleon's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Haleon (HLN), the current ROE % Adjusted to Book Value is 5.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haleon (HLN) Overvalued in 2026?

Based on GuruFocus' analysis, Haleon stock appears to be overvalued. The current stock price of $9.82 is trading 0.8% above its estimated GF Value™ of $9.74. GuruFocus considers Haleon to be Fairly Valued.

Key valuation signals for HLN:

  • ROE % Adjusted to Book Value: 5.16%
  • GF Value™: $9.74 vs. price of $9.82 (0.8% above fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the HLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haleon Business Description

Address The Heights, Building 5, First Floor, Weybridge, Surrey, GBR, KT13 0NY
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
70GF Score

Get the complete analysis for HLN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.82
Price
$9.74
GF Value